Video

When to Treat Relapsed Myeloma

Author(s):

Sagar Lonial, M.D.

Here is what one expert says about the right time to start treating relapsed multiple myeloma.

Sagar Lonial, M.D., professor and chair of the Department of Hematology and Medical Oncology and chief medical officer of the Winship Cancer Institute of Emory University discusses the criteria for treating patients with relapsed myeloma.

First, it is essential to determine if the patient needs to be treated at all. According to the International Myeloma Working Group, anyone who shows a re-emergence of symptomatic myeloma, per the CRAB criteria (calcium levels, renal dysfunction, anemia and bone lesions) should be treated.

However, Lonial mentioned that just because someone has a biochemical relapse, that doesn't always mean that they need treatment. Instead, Lonial may watch these patients, and take into consideration other possible factors, such as their genetic risk.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Minimally Invasive Surgery Transforms Lung Cancer Recovery
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Image of Staci.
Image of woman, with text.
Related Content
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 2nd 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.
Top Headlines on CAR-T Cell Therapy
August 2nd 2025

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
August 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
August 2nd 2025

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Image of ronald.
August 2nd 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Image of two doctors with text.
August 2nd 2025

Experts Impart Notable Information and Updates for Those With Blood Cancers

Dr. Joshua K. Sabari Dr. Nausheen Ahmed
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.